AAPG

Ascentage Pharma Group International

Add to Watchlist

Advanced Chart

32.360

-0.55(-1.671%)1D

Line

Candle

YTD

High

33.1135

Open

33.1135

VWAP

32.61

Vol

12.45K

Mkt Cap

12.08B

Low

32.200

Amount

406.05K

EV/EBITDA(TTM)

Total Shares

373.32M

3.13B

EV/OCF(TTM)

P/S(TTM)

50.14

Ascentage Pharma Group International is a holding company primarily engaged in discovering, developing and commercializing therapies primarily in hematological malignancies. The Company’s main business is engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus and certain age-related diseases. The Company’s main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918 and other products. The Company’s products are mainly used to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. The Company mainly conducts its business in the domestic market.

1 Analyst Rating

Wall Street analysts forecast AAPG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AAPG is 47.00 USD with a low forecast of 47.00 USD and a high forecast of 47.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 32.360

Low

47.00

Averages

47.00

High

47.00

Current: 32.360

Low

47.00

Averages

47.00

High

47.00

Piper Sandler

Biren Amin

Overweight

initiated

$48

2025-11-05

New

Reason

Piper Sandler

Biren Amin

Price Target

$48

2025-11-05

New

initiated

Overweight

Reason

Piper Sandler analyst Biren Amin initiated coverage of Ascentage Pharma with an Overweight rating and $48 price target. The company's two approved assets in China are now under evaluation in the U.S., the analyst tells investors in a research note. Piper projects $1.9B and $1B in peak risk-adjusted global revenues for olverembatinib and lisaftoclax, respectively.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Ascentage Pharma Group International (AAPG.O) is -39.16, compared to its 5-year average forward P/E of -17.14. For a more detailed relative valuation and DCF analysis to assess Ascentage Pharma Group International 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-17.14

Current PE

-39.16

Overvalued PE

-4.40

Undervalued PE

-29.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-38.28

Current EV/EBITDA

-51.40

Overvalued EV/EBITDA

-19.82

Undervalued EV/EBITDA

-56.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

33.01

Current PS

59.58

Overvalued PS

71.89

Undervalued PS

-5.88